Publications

Kluger H, J Barrett C, Gainor JF, Hamid O, Hurwitz M, LaVallee T, Moss RA, Zappasodi R, Sullivan RJ, Tawbi H et al..  2023.  Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors.. J Immunother Cancer. 11(3)

Davar D, Zappasodi R.  2023.  Targeting GITR in cancer immunotherapy - there is no perfect knowledge.. Oncotarget. 14:614-621.

Gregucci F, Spada S, Barcellos-Hoff MHelen, Bhardwaj N, Hak CChan Wah, Fiorentino A, Guha C, Guzman ML, Harrington K, Herrera FG et al..  2023.  Updates on radiotherapy-immunotherapy combinations: Proceedings of 6th annual ImmunoRad conference.. Oncoimmunology. 12(1):2222560.

Michels J, Venkatesh D, Liu C, Budhu S, Zhong H, George MM, Thach D, Yao Z-K, Ouerfelli O, Liu H et al..  2024.  APR-246 increases tumor antigenicity independent of p53.. Life Sci Alliance. 7(1)

Li J, Chin CR, Ying H-Y, Meydan C, Teater MR, Xia M, Farinha P, Takata K, Chu C-S, Jiang Y et al..  2024.  Loss of CREBBP and KMT2D cooperate to accelerate lymphomagenesis and shape the lymphoma immune microenvironment.. Nat Commun. 15(1):2879.

Verma S, Budhu S, Serganova I, Dong L, Mangarin LM, Khan JF, Bah MA, Assouvie A, Marouf Y, Schulze I et al..  2024.  Pharmacologic LDH inhibition redirects intratumoral glucose uptake and improves antitumor immunity in solid tumor models.. J Clin Invest. 134(17)

Cancila V, Bertolazzi G, Chan ASy, Medico G, Bastianello G, Morello G, Paysan D, Lai C, Hong L, Shenoy G et al..  2025.  Aggressive B cell lymphomas retain ATR-dependent determinants of T cell exclusion from the germinal center dark zone.. J Clin Invest. 135(18)

Isshiki Y, Chen X, Teater M, Karagiannidis I, Nam H, Cai W, Meydan C, Xia M, Shen H, Gutierrez J et al..  2025.  EZH2 inhibition enhances T cell immunotherapies by inducing lymphoma immunogenicity and improving T cell function.. Cancer Cell. 43(1):49-68.e9.

Hamid O, Cardin DB, F Hodi S, LoRusso P, Merghoub T, Zappasodi R, Maniyar R, Janik JE, van der Velden MVW, Zhou F et al..  2025.  First-in-Human Phase 1/2 Study of INCAGN01876, a Glucocorticoid-Induced Tumor Necrosis Factor Receptor Agonist, in Patients with Advanced or Metastatic Solid Tumors.. Clin Cancer Res.